Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

ClinicalTrials.gov ID: NCT00528697

Public ClinicalTrials.gov record NCT00528697. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Children With Attention Deficit-Hyperactivity Disorder (ADHD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for children with Attention-Deficit/Hyperactivity Disorder or ADHD.

Study identification

NCT ID
NCT00528697
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Enrollment
278 participants

Conditions and interventions

Eligibility (public fields only)

Age range
6 Years to 12 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 2007 (Type not available)
Primary completion
Apr 2008 (Actual)
Completion
Apr 2008 (Actual)
Last update posted
Jan 29, 2013

2007 – 2008

United States locations

U.S. sites
20
U.S. states
16
U.S. cities
20
Facility City State ZIP Site status
Site Reference ID/Investigator# 5999 Little Rock Arkansas 72205 —
Site Reference ID/Investigator# 5979 El Centro California 92243 —
Site Reference ID/Investigator# 5986 Boulder Colorado 80304 —
Site Reference ID/Investigator# 5993 Bradenton Florida 34208 —
Site Reference ID/Investigator# 5995 Jacksonville Florida 32216 —
Site Reference ID/Investigator# 5977 Orlando Florida 32806 —
Site Reference ID/Investigator# 5981 Northbrook Illinois 60062 —
Site Reference ID/Investigator# 5982 Overland Park Kansas 66212 —
Site Reference ID/Investigator# 5992 Omaha Nebraska 68198 —
Site Reference ID/Investigator# 5997 Las Vegas Nevada 89128 —
Site Reference ID/Investigator# 5987 Clementon New Jersey 08021 —
Site Reference ID/Investigator# 5996 Eugene Oregon 97401 —
Site Reference ID/Investigator# 5984 Portland Oregon 97210 —
Site Reference ID/Investigator# 5980 Salem Oregon 97301 —
Site Reference ID/Investigator# 5994 Charleston South Carolina 29405 —
Site Reference ID/Investigator# 5976 Memphis Tennessee 38119 —
Site Reference ID/Investigator# 6000 Austin Texas 78756 —
Site Reference ID/Investigator# 5998 Herndon Virginia 20170 —
Site Reference ID/Investigator# 5978 Bellevue Washington 98007 —
Site Reference ID/Investigator# 5983 Middleton Wisconsin 53562 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00528697, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 29, 2013 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00528697 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →